Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion

被引：3

作者：

Watanabe, Satoshi ^{[1
]}

Inoue, Akira ^{[2
]}

Nukiwa, Toshihiro ^{[3
]}

Kobayashi, Kunihiko ^{[4
]}

机构：

[1] Niigata Univ, Grad Sch Med & Dent Sci, Dept Resp Med & Infect Dis, Niigata 9518510, Japan

[2] Tohoku Univ, Dept Med Res, Sendai, Miyagi, Japan

[3] Japan AntiTB Assoc, Chiyoda Ku, Tokyo, Japan

[4] Saitama Int Med Ctr, Resp Med, Hidaka, Saitama, Japan

来源：

ANTICANCER RESEARCH | 2015年 / 35卷 / 12期

关键词：

Gefitinib; EGFR mutation; non-small cell lung cancer; exon; 19; deletion; L858R; EGFR MUTATIONS; 1ST-LINE TREATMENT; OPEN-LABEL; PHASE-III; AFATINIB; ADENOCARCINOMA; MULTICENTER; ERLOTINIB;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) afatinib as first-line treatment has been demonstrated to improve overall survival (OS) in patients with non-small cell lung cancer (NSCLC) harboring an exon 19 deletion (del19) of EGFR compared to platinum-doublet chemotherapy. However, it is unclear whether first-generation EGFR-TKIs improve OS in patients with del19 in the first-line treatment. Patients and Methods: We performed a post-hoc analysis of patients with del19 or L858R mutation of EGFR who received gefitinib in the NEJ002 study, which compared gefitinib to carboplatin-paclitaxel. Results: A total of 58 patients and 57 patients with del19 EGFR received gefitinib and carboplatin-paclitaxel, respectively. No OS differences were observed between patients receiving gefitinib and carboplatin-paclitaxel irrespective of del19 (29.3 months vs. 29.7 months, p= 0.53) or L858R (28.4 months vs. 25.1 months, p= 0.45). Conclusion: In contrast to afatinib, it is suggested that first-line gefitinib does not improve OS in patients with del19 of EGFR compared with platinum-doublet chemotherapy.

引用

页码：6957 / 6961

页数：5

共 50 条

[1] Afatinib is Especially Effective Against Non-small Cell Lung Cancer Carrying an EGFR Exon 19 Deletion [J].

Banno, Eri ;

Togashi, Yosuke ;

Kobayashi, Yoshihisa ;

Hayashi, Hidetoshi ;

Mitsudomi, Tetsuya ;

Nishio, Kazuto .

ANTICANCER RESEARCH, 2015, 35 (04) :2005-2008

[2] EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients [J].

Choi, Yong Won ;

Jeon, So Yeon ;

Jeong, Geum Sook ;

Lee, Hyun Woo ;

Jeong, Seong Hyun ;

Kang, Seok Yun ;

Park, Joon Seong ;

Choi, Jin-Hyuk ;

Koh, Young Wha ;

Han, Jae Ho ;

Sheen, Seung Soo .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (04) :385-390

[3] Non-small Cell Lung Cancer in South Wales: Are Exon 19 Deletions and L858R Different? [J].

Davies, Rhian Sian ;

Nelmes, Daniel John ;

Butler, Rachel ;

Lester, Jason Francis .

ANTICANCER RESEARCH, 2016, 36 (08) :4267-4271

[4] Comparison of the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer according to the Type of Epidermal Growth Factor Receptor Mutation [J].

Igawa, Satoshi ;

Kasajima, Masashi ;

Ishihara, Mikiko ;

Kimura, Michiko ;

Hiyoshi, Yasuhiro ;

Asakuma, Maiko ;

Otani, Sakiko ;

Katono, Ken ;

Sasaki, Jiichiro ;

Masuda, Noriyuki .

ONCOLOGY, 2014, 87 (04) :215-223

[5] Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China [J].

Wang, Yang ;

Yuan, Xiaobin ;

Yang, Min ;

Shen, Zhilin ;

Chen, Hui ;

He, Xiangbo ;

Ma, Yongbin ;

Ding, Lieming .

PHARMACOLOGY, 2021, 106 (11-12) :658-666

[6] A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer [J].

Fujiwara, Atsushi ;

Yoshida, Masamichi ;

Fujimoto, Hajime ;

Nakahara, Hiroki ;

Ito, Kentaro ;

Nishihama, Kota ;

Yasuma, Taro ;

Hataji, Osamu ;

Taguchi, Osamu ;

D'Alessandro-Gabazza, Corina N. ;

Gabazza, Esteban C. ;

Kobayashi, Tetsu .

ONCOLOGY RESEARCH, 2018, 26 (07) :1031-1036

[7] A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations [J].

Yang, J. J. ;

Zhou, Q. ;

Yan, H. H. ;

Zhang, X. C. ;

Chen, H. J. ;

Tu, H. Y. ;

Wang, Z. ;

Xu, C. R. ;

Su, J. ;

Wang, B. C. ;

Jiang, B. Y. ;

Bai, X. Y. ;

Zhong, W. Z. ;

Yang, X. N. ;

Wu, Y. L. .

BRITISH JOURNAL OF CANCER, 2017, 116 (05) :568-574

[8] Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer [J].

Jiang, Haiying ;

Zhu, Mei ;

Li, Yanfang ;

Li, Qian .

MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (03) :301-308

[9] Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis [J].

Yang, Zuyao ;

Hackshaw, Allan ;

Feng, Qi ;

Fu, Xiaohong ;

Zhang, Yuelun ;

Mao, Chen ;

Tang, Jinling .

INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (12) :2805-2819

[10] Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution [J].

Koyama, Nobuyuki ;

Watanabe, Yasutaka ;

Iwai, Yuki ;

Kawamura, Rumi ;

Miwa, Chihiro ;

Nagai, Yoshiaki ;

Hagiwara, Koichi ;

Koyama, Shinichiro .

CHEMOTHERAPY, 2017, 62 (03) :151-158

← 1 2 3 4 5 →